2025-2028 (ANR PRC - SUPRALABEL)
In collaboration with Dr Simon Specklin, CEA Biomaps, and Dr Pierre-Simon Bellaye, CGFL, Dijon 

2025-2027 (SATT SAYENS - Maturation program - SUPRALINK)

2024-2025 (CNRS INNOVATION - Prematuration program - SUPRALINK)

These projects aim at developing a strategy known as "pretargeting", in which the radiolabeling of an antibody is not carried out prior to administration to the patient, but is performed in vivo, once the antibody has optimally accumulated in the target tissue and has been eliminated from healthy tissues. The association between the targeting antibody and the radioactive probe is achieved through supramolecular chemistry. This strategy should improve the efficacy and safety of future radiopharmaceuticals.

2024-2025 (LOXSTIC) 

The LOXSTIC project successfully established a robust, site-specific chemoenzymatic strategy to label the anti-LOXL2 antibody simtuzumab with indium-111, yielding high radiochemical purity and fully preserved target affinity in vitro. In vivo imaging in the pancreatic cancer model BxPC3 showed modest tumor uptake, probably caused by insufficient active fibrosis. Further evaluation of the anti-LOXL2 tracer on alternative fibrotic tumor models is ongoing.

2023-2025 (CD133DIAG)

In collaboration with Dr Emilie Roeder, Nancyclotep, Nancy
We successfully synthesized a novel 68Ga-labeled Fab radiotracer (68Ga-NODAGA-Fab) targeting CD133 with high purity and reproducible yields. 

2021-2023 (IMAFIBRO)

In collaboration with Dr Pierre-Simon Bellaye, CGFL, Dijon

In this project, we synthesized the first nuclear imaging tracer targeting LOXL2, an enzyme expressed during fibrosis. This tracer was evaluated by SPECT-CT in a mouse model of progressive pulmonary fibrosis 

2017-2022 (JCJC - ZINELABEL)

ZINELABEL explored the chemistry of dichlorotetrazine, a minimalist chemical platform allowing the site-specific introduction two payloads/imaging probes on a single protein residue. This platform has now been applied to the synthesis of numerous bioconjugates.

2017-2018 (FLUOnTEP)

In collaboration with Dr Aurélie Prignon, Sorbonne Université, Paris

Here, we designed peptide-based bimodal PET (68Ga) - fluorescent tracers targeting neurotensin receptor 1 (NTS1). These tracers were evaluated in a mice model of pancreatic cancer (PDAC, AsPC1 xenograft). The project was extended with the radiolabeling of small molecule antagonists of NTS1.